Royalty Pharma R&D decreased by 21.2% to $39.79M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 21.2%, from $50.50M to $39.79M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 22.6% CAGR.
Analysis
How to read this metric
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Detailed definition
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Peer comparison
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_developmentHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.12M | $90.50M | $103.82M | $100.50M | $606.00K | $25.50M | $50.50M | $500.00K | $500.00K | $50.50M | $500.00K | $500.00K | $500.00K | $500.00K | $500.00K | $50.50M | $300.50M | $50.50M | $50.50M | $39.79M |
| QoQ Change | — | >999% | +14.7% | -3.2% | -99.4% | >999% | +98.0% | -99.0% | +0.0% | >999% | -99.0% | +0.0% | +0.0% | +0.0% | +0.0% | >999% | +495.0% | -83.2% | +0.0% | -21.2% |
| YoY Change | — | — | — | — | -80.6% | -71.8% | -51.4% | -99.5% | -17.5% | +98.0% | -99.0% | +0.0% | +0.0% | -99.0% | +0.0% | >999% | >999% | >999% | >999% | -21.2% |
Product Breakdown
| Segment | Q1 '26 |
|---|---|
| Phase 2b, TEV-408 | $14.30M |
| Total | $39.79M |
Daraxonrasib was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
R&D at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's r&d?
- Royalty Pharma (RPRX) reported r&d of $39.79M in Q1 2026.
- How has Royalty Pharma's r&d changed year-over-year?
- Royalty Pharma's r&d decreased by 21.2% year-over-year, from $50.50M to $39.79M.
- What is the long-term trend for Royalty Pharma's r&d?
- Over 4 years (2021 to 2025), Royalty Pharma's r&d has grown at a 22.6% compound annual growth rate (CAGR), from $200.08M to $452.00M.
- What does r&d mean?
- The money spent on creating new products or improving existing ones to drive future growth.